Vaxart reverse merges its way onto Nasdaq, climbing aboard the Aviragen shell
Vaxart says it’s about to unveil positive results from an early-stage study of a new vaccine, and it’s celebrating with a reverse merger onto Nasdaq …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
